Gilead Sciences
$74.469876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$74.46
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$1.17 (-1.54%) Today
-$0.30 (-0.40%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell GILD and other stocks, options, ETFs, and crypto commission-free!
About GILD
Gilead Sciences, Inc. Common Stock, also called Gilead Sciences, is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Read More The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
Employees
11,800
Headquarters
Foster City, California
Founded
1987
Market Cap
92.06B
Price-Earnings Ratio
17.27
Dividend Yield
3.73
Average Volume
28.74M
High Today
$76.33
Low Today
$73.79
Open Price
$75.90
Volume
12.12M
52 Week High
$85.97
52 Week Low
$60.89
Collections
GILD News
ReutersMar 30
BRIEF-Gilead Announces Expiration Of Hart-Scott-Rodino Waiting Period For Forty Seven Tender Offer
March 30 (Reuters) - Gilead Sciences Inc:
* GILEAD ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD FOR FORTY SEVEN TENDER OFFER
* GILEAD SCIENCES INC
Analyst Ratings
48%
of 27 ratings
Buy
48%
Hold
41%
Sell
11%
GILD Earnings
$0.00
$0.61
$1.23
$1.84
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected Apr 30, After Hours
People Also Bought
You May Also Like
More GILD News
Financial TimesMar 26
The global hunt for a coronavirus drug | Free to read
It was Friday March 13 when doctors at Northwell Health, the largest healthcare provider in New York City, decided to take the search for a coronavirus drug int
New York TimesMar 25
Gilead Asks FDA to Take Back Lucrative Orphan Drug Status on Possible Coronavirus Treatment
(Reuters) - Gilead Sciences Inc on Wednesday took the unusual step of asking the U.S. Food and Drug Administration to rescind a controversial orphan drug design
ReutersMar 25
Gilead asks FDA to revoke orphan drug status for potential coronavirus drug
March 25 (Reuters) - Gilead Sciences Inc said on Wednesday it had requested the U.S. Food and Drug administration to rescind the “orphan drug” status for its ex